Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | CD38 | P28907 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12017706 | 0.78 | CYP1A2 (0.62) | CYP3A4CYP2C19CYP2D6CYP1A2CYP2C9 | |
| SCHEMBL994454 | 0.78 | CYP1A2 (0.62) | CYP3A4CYP2C19CYP2D6CYP1A2CYP2C9 | |
| SCHEMBL3957778 | 0.78 | CYP3A4 (0.51) | CYP3A4CYP2C19CYP2D6CYP1A2CYP2C9 | |
| SCHEMBL3526697 | 0.75 | PSEN1 (0.40) | CYP2C9TRPV4 | |
| SCHEMBL12015798 | 0.74 | ALDH1A1 (0.57) | CYP3A4CYP2C19CYP2D6CYP1A2CYP2C9 | |
| SCHEMBL1237285 | 0.74 | CYP1A2 (0.57) | CYP3A4CYP2C19CYP2D6CYP1A2CYP2C9 | |
| SCHEMBL10232920 | 0.74 | CYP1A2 (0.57) | CYP3A4CYP2C19CYP2D6CYP1A2CYP2C9 | |
| SCHEMBL251863 | 0.74 | CYP1A2 (0.57) | CYP3A4CYP2C19CYP2D6CYP1A2CYP2C9 | |
| SCHEMBL18584427 | 0.74 | CYP19A1 (0.48) | CYP3A4CYP2C19CYP2D6CYP1A2CYP2C9 | |
| SCHEMBL17629932 | 0.74 | ADH5 (0.60) | CYP3A4CYP2C19CYP2D6CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401275-B1 | NAPHTHYRIDINE DERIVATIVES HAVING BRONCHODILATING ACTIVITY | RESPIRATORIUS AB (SE) | 2013-07-24 | — | — | EP | disclosed |
| EP-2401275-B1 | NAPHTHYRIDINE DERIVATIVES HAVING BRONCHODILATING ACTIVITY | RESPIRATORIUS AB (SE) | 2013-07-24 | — | — | EP | disclosed |
| US-8415333-B2 | Bronchodilating diazaheteroaryls | RESPIRATORIOUS AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-8415333-B2 | Bronchodilating diazaheteroaryls | RESPIRATORIOUS AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-20120040942-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | RESPIRATORIUS AB (SE) | 2012-02-16 | — | — | US | disclosed |
| US-20120040942-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | RESPIRATORIUS AB (SE) | 2012-02-16 | — | — | US | disclosed |
| EP-2401275-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | Respiratorius AB (SE) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010097410-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | RESPIRATORIUS AB (SE) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010097410-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | RESPIRATORIUS AB (SE) | 2010-09-02 | — | — | WO | disclosed |
| US-7655669-B2 | Pyrimidineamide derivatives and the use thereof | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| CN-100404528-C | Novel pyrimidinamine derivatives and use thereof | NOVARTIS AG (CH) | 2008-07-23 | — | — | CN | disclosed |
| EP-1546127-B1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | NOVARTIS AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| US-20060142577-A1 | Novel pyrimidineamide derivatives and the use thereof | NOVARTIS AG (CH) | 2006-06-29 | — | — | US | disclosed |
| CN-1684951-A | Novel pyrimidinamine derivatives and use thereof | NOVARTIS AG (CH) | 2005-10-19 | — | — | CN | disclosed |
| EP-1546127-A1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | Novartis AG (CH) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004029038-A1 | NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF | NOVARTIS AG (CH) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142577-A1 | Novel pyrimidineamide derivatives and the use thereof | TYMP, NME2, DPYD | CYP3A4 3088/4885CYP2C19 2464/4885CYP2D6 2744/4885 |
| US-20120040942-A1 | NOVEL BRONCHODILATING DIAZAHETEROARYLS | CHRM3, ADRB1, ADRB3 | CYP3A4 496/4885CYP2C19 453/4885CYP2D6 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.